<?xml version="1.0" ?>
<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2023//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_230101.dtd">
<PubmedArticleSet>
<PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Automated"><PMID Version="1">35159225</PMID><DateCompleted><Year>2022</Year><Month>04</Month><Day>08</Day></DateCompleted><DateRevised><Year>2022</Year><Month>04</Month><Day>08</Day></DateRevised><Article PubModel="Electronic"><Journal><ISSN IssnType="Electronic">2073-4409</ISSN><JournalIssue CitedMedium="Internet"><Volume>11</Volume><Issue>3</Issue><PubDate><Year>2022</Year><Month>Jan</Month><Day>25</Day></PubDate></JournalIssue><Title>Cells</Title><ISOAbbreviation>Cells</ISOAbbreviation></Journal><ArticleTitle>Therapeutic Targets in Amyotrophic Lateral Sclerosis: Focus on Ion Channels and Skeletal Muscle.</ArticleTitle><ELocationID EIdType="pii" ValidYN="Y">415</ELocationID><ELocationID EIdType="doi" ValidYN="Y">10.3390/cells11030415</ELocationID><Abstract><AbstractText>Amyotrophic Lateral Sclerosis is a neurodegenerative disease caused by progressive loss of motor neurons, which severely compromises skeletal muscle function. Evidence shows that muscle may act as a molecular powerhouse, whose final signals generate in patients a progressive loss of voluntary muscle function and weakness leading to paralysis. This pathology is the result of a complex cascade of events that involves a crosstalk among motor neurons, glia, and muscles, and evolves through the action of converging toxic mechanisms. In fact, mitochondrial dysfunction, which leads to oxidative stress, is one of the mechanisms causing cell death. It is a common denominator for the two existing forms of the disease: sporadic and familial. Other factors include excitotoxicity, inflammation, and protein aggregation. Currently, there are limited cures. The only approved drug for therapy is riluzole, that modestly prolongs survival, with edaravone now waiting for new clinical trial aimed to clarify its efficacy. Thus, there is a need of effective treatments to reverse the damage in this devastating pathology. Many drugs have been already tested in clinical trials and are currently under investigation. This review summarizes the already tested drugs aimed at restoring muscle-nerve cross-talk and on new treatment options targeting this tissue.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Tarantino</LastName><ForeName>Nancy</ForeName><Initials>N</Initials><Identifier Source="ORCID">0000-0001-7211-0928</Identifier><AffiliationInfo><Affiliation>Department of Pharmacy-Drug Sciences, University of Bari Aldo Moro, 70125 Bari, Italy.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Canfora</LastName><ForeName>Ileana</ForeName><Initials>I</Initials><Identifier Source="ORCID">0000-0002-6357-316X</Identifier><AffiliationInfo><Affiliation>Department of Pharmacy-Drug Sciences, University of Bari Aldo Moro, 70125 Bari, Italy.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Camerino</LastName><ForeName>Giulia Maria</ForeName><Initials>GM</Initials><AffiliationInfo><Affiliation>Department of Pharmacy-Drug Sciences, University of Bari Aldo Moro, 70125 Bari, Italy.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Pierno</LastName><ForeName>Sabata</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>Department of Pharmacy-Drug Sciences, University of Bari Aldo Moro, 70125 Bari, Italy.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D016454">Review</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2022</Year><Month>01</Month><Day>25</Day></ArticleDate></Article><MedlineJournalInfo><Country>Switzerland</Country><MedlineTA>Cells</MedlineTA><NlmUniqueID>101600052</NlmUniqueID><ISSNLinking>2073-4409</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D007473">Ion Channels</NameOfSubstance></Chemical><Chemical><RegistryNumber>7LJ087RS6F</RegistryNumber><NameOfSubstance UI="D019782">Riluzole</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000690" MajorTopicYN="Y">Amyotrophic Lateral Sclerosis</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D007473" MajorTopicYN="N">Ion Channels</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D018482" MajorTopicYN="N">Muscle, Skeletal</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D019636" MajorTopicYN="Y">Neurodegenerative Diseases</DescriptorName><QualifierName UI="Q000473" MajorTopicYN="N">pathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D019782" MajorTopicYN="N">Riluzole</DescriptorName><QualifierName UI="Q000494" MajorTopicYN="N">pharmacology</QualifierName><QualifierName UI="Q000627" MajorTopicYN="N">therapeutic use</QualifierName></MeshHeading></MeshHeadingList><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">amyotrophic lateral sclerosis</Keyword><Keyword MajorTopicYN="N">animal models</Keyword><Keyword MajorTopicYN="N">clinical trials</Keyword><Keyword MajorTopicYN="N">ion channels</Keyword><Keyword MajorTopicYN="N">skeletal muscle</Keyword><Keyword MajorTopicYN="N">therapy</Keyword></KeywordList><CoiStatement>The authors declare no conflict of interest.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2021</Year><Month>12</Month><Day>28</Day></PubMedPubDate><PubMedPubDate PubStatus="revised"><Year>2022</Year><Month>1</Month><Day>18</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2022</Year><Month>1</Month><Day>22</Day></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2022</Year><Month>2</Month><Day>15</Day><Hour>1</Hour><Minute>4</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2022</Year><Month>2</Month><Day>16</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2022</Year><Month>4</Month><Day>9</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>epublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">35159225</ArticleId><ArticleId IdType="pmc">PMC8834084</ArticleId><ArticleId IdType="doi">10.3390/cells11030415</ArticleId><ArticleId IdType="pii">cells11030415</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Bonifacino T., Rebosio C., Provenzano F., Torazza C., Balbi M., Milanese M., Raiteri L., Usai C., Fedele E., Bonanno G. Enhanced Function and Overexpression of Metabotropic Glutamate Receptors 1 and 5 in the Spinal Cord of the SOD1G93A Mouse Model of Amyotrophic Lateral Sclerosis during Disease Progression. Int. J. Mol. Sci. 2019;20:4552. doi: 10.3390/ijms20184552.</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/ijms20184552</ArticleId><ArticleId IdType="pmc">PMC6774337</ArticleId><ArticleId IdType="pubmed">31540330</ArticleId></ArticleIdList></Reference><Reference><Citation>Martineau &#xc9;., Arbour D., Vall&#xe9;e J., Robitaille R. Properties of Glial Cell at the Neuromuscular Junction Are Incompatible with Synaptic Repair in the SOD1G37R ALS Mouse Model. J. Neurosci. 2020;40:7759&#x2013;7777. doi: 10.1523/JNEUROSCI.1748-18.2020.</Citation><ArticleIdList><ArticleId IdType="doi">10.1523/JNEUROSCI.1748-18.2020</ArticleId><ArticleId IdType="pmc">PMC7531543</ArticleId><ArticleId IdType="pubmed">32859714</ArticleId></ArticleIdList></Reference><Reference><Citation>Boill&#xe9;e S., Velde V.C., Cleveland D.W. ALS: A disease of motor neurons and their nonneuronal neighbors. Neuron. 2006;52:39&#x2013;59. doi: 10.1016/j.neuron.2006.09.018.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.neuron.2006.09.018</ArticleId><ArticleId IdType="pubmed">17015226</ArticleId></ArticleIdList></Reference><Reference><Citation>Pasinelli P., Brown R.H. Molecular biology of amyotrophic lateral sclerosis: Insights from genetics. Nat. Rev. Neurosci. 2006;7:710&#x2013;723. doi: 10.1038/nrn1971.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/nrn1971</ArticleId><ArticleId IdType="pubmed">16924260</ArticleId></ArticleIdList></Reference><Reference><Citation>Bonifacino T., Zerbo R.A., Balbi M., Torazza C., Frumento G., Fedele E., Bonanno G., Milanese M. Nearly 30 Years of Animal Models to Study Amyotrophic Lateral Sclerosis: A Historical Overview and Future Perspectives. Int. J. Mol. Sci. 2021;22:12236. doi: 10.3390/ijms222212236.</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/ijms222212236</ArticleId><ArticleId IdType="pmc">PMC8619465</ArticleId><ArticleId IdType="pubmed">34830115</ArticleId></ArticleIdList></Reference><Reference><Citation>Musar&#xf2; A. Understanding ALS: New therapeutic approaches. FEBS J. 2013;280:4315&#x2013;4322. doi: 10.1111/febs.12087.</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/febs.12087</ArticleId><ArticleId IdType="pubmed">23217177</ArticleId></ArticleIdList></Reference><Reference><Citation>Gurney M.E., Pu H., Chiu A.Y., Dal Canto M.C., Polchow C.Y., Alexander D.D., Caliendo J., Hentati A., Kwon Y.W., Deng H.X., et al. Motor neuron degeneration in mice that express a human Cu,Zn superoxide dismutase mutation. Science. 1994;264:1772&#x2013;1775. doi: 10.1126/science.8209258. Erratum in Science 1995, 269, 149.</Citation><ArticleIdList><ArticleId IdType="doi">10.1126/science.8209258</ArticleId><ArticleId IdType="pubmed">8209258</ArticleId></ArticleIdList></Reference><Reference><Citation>Ludolph A.C., Bendotti C., Blaugrund E., Chi&#xf2; A., Greensmith L., Loeffler J.P., Mead R., Niessen H.G., Petri S., Pradat P.F., et al. Guidelines for preclinical animal research in ALS/MND: A consensus meeting. Amyotroph. Lateral Scler. 2010;11:38&#x2013;45. doi: 10.3109/17482960903545334.</Citation><ArticleIdList><ArticleId IdType="doi">10.3109/17482960903545334</ArticleId><ArticleId IdType="pubmed">20184514</ArticleId></ArticleIdList></Reference><Reference><Citation>Cleveland D.W., Rothstein J.D. From Charcot to Lou Gehrig: Deciphering selective motor neuron death in ALS. Nat. Rev. Neurosci. 2001;2:806&#x2013;819. doi: 10.1038/35097565.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/35097565</ArticleId><ArticleId IdType="pubmed">11715057</ArticleId></ArticleIdList></Reference><Reference><Citation>Cozzolino M., Pesaresi M.G., Gerbino V., Grosskreutz J., Carr&#xec; M.T. Amyotrophic lateral sclerosis: New insights into underlying molecular mechanisms and opportunities for therapeutic intervention. Antioxid. Redox Signal. 2012;17:1277&#x2013;1330. doi: 10.1089/ars.2011.4328.</Citation><ArticleIdList><ArticleId IdType="doi">10.1089/ars.2011.4328</ArticleId><ArticleId IdType="pubmed">22413952</ArticleId></ArticleIdList></Reference><Reference><Citation>Beghi E., Chi&#xf2; A., Couratier P., Esteban J., Hardiman O., Logroscino G., Millul A., Mitchell D., Preux P.M., Pupillo E., et al. Eurals Consortium. The epidemiology and treatment of ALS: Focus on the heterogeneity of the disease and critical appraisal of therapeutic trials. Amyotroph. Lateral Scler. 2011;12:1&#x2013;10. doi: 10.3109/17482968.2010.502940.</Citation><ArticleIdList><ArticleId IdType="doi">10.3109/17482968.2010.502940</ArticleId><ArticleId IdType="pmc">PMC3513399</ArticleId><ArticleId IdType="pubmed">20698807</ArticleId></ArticleIdList></Reference><Reference><Citation>Lacomblez L., Bensimon G., Leigh P.N., Guillet P., Meininger V. Dose-ranging study of riluzole in amyotrophic lateral sclerosis. Amyotrophic Lateral Sclerosis/Riluzole Study Group II. Lancet. 1996;347:1425&#x2013;1431. doi: 10.1016/S0140-6736(96)91680-3.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S0140-6736(96)91680-3</ArticleId><ArticleId IdType="pubmed">8676624</ArticleId></ArticleIdList></Reference><Reference><Citation>Brooks B.R., Pioro E.P., Katz J., Takahashi F., Takei K., Zhang J., Apple S. Slowing the loss of physical function in amyotrophic lateral sclerosis with edaravone: Post hoc analysis of ALSFRS-R item scores in pivotal study MCI186&#x2013;19. Muscle Nerve. 2021;65:180&#x2013;186. doi: 10.1002/mus.27467.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/mus.27467</ArticleId><ArticleId IdType="pubmed">34816454</ArticleId></ArticleIdList></Reference><Reference><Citation>Dobrowolny G., Giacinti C., Pelosi L., Nicoletti C., Winn N., Barberi L., Molinaro M., Rosenthal N., Musar&#xf2; A. Muscle expression of a local Igf-1 isoform protects motor neurons in an ALS mouse model. J. Cell Biol. 2005;168:193&#x2013;199. doi: 10.1083/jcb.200407021.</Citation><ArticleIdList><ArticleId IdType="doi">10.1083/jcb.200407021</ArticleId><ArticleId IdType="pmc">PMC2171577</ArticleId><ArticleId IdType="pubmed">15657392</ArticleId></ArticleIdList></Reference><Reference><Citation>Wong M., Martin L.J. Skeletal muscle-restricted expression of human SOD1 causes motor neuron degeneration in transgenic mice. Hum. Mol. Genet. 2010;19:2284&#x2013;2302. doi: 10.1093/hmg/ddq106.</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/hmg/ddq106</ArticleId><ArticleId IdType="pmc">PMC2865380</ArticleId><ArticleId IdType="pubmed">20223753</ArticleId></ArticleIdList></Reference><Reference><Citation>Dobrowolny G., Bernardini C., Martini M., Baranzini M., Barba M., Musar&#xf2; A. Muscle Expression of SOD1(G93A) Modulates microRNA and mRNA Transcription Pattern Associated with the Myelination Process in the Spinal Cord of Transgenic Mice. Front. Cell Neurosci. 2015;9:463. doi: 10.3389/fncel.2015.00463.</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fncel.2015.00463</ArticleId><ArticleId IdType="pmc">PMC4664730</ArticleId><ArticleId IdType="pubmed">26648847</ArticleId></ArticleIdList></Reference><Reference><Citation>Fracchiolla G., Laghezza A., Piemontese L., Tortorella P., Mazza F., Montanari R., Pochetti G., Lavecchia A., Novellino E., Pierno S., et al. New 2-aryloxy-3-phenyl-propanoic acids as peroxisome proliferator-activated receptors alpha/gamma dual agonists with improved potency and reduced adverse effects on skeletal muscle function. J. Med. Chem. 2009;52:6382&#x2013;6393. doi: 10.1021/jm900941b.</Citation><ArticleIdList><ArticleId IdType="doi">10.1021/jm900941b</ArticleId><ArticleId IdType="pubmed">19775169</ArticleId></ArticleIdList></Reference><Reference><Citation>Camerino G.M., De Bellis M., Conte E., Liantonio A., Musaraj K., Cannone M., Fonzino A., Giustino A., De Luca A., Romano R., et al. Statin-induced myotoxicity is exacerbated by aging: A biophysical and molecular biology study in rats treated with atorvastatin. Toxicol. Appl. Pharmacol. 2016;306:36&#x2013;46. doi: 10.1016/j.taap.2016.06.032.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.taap.2016.06.032</ArticleId><ArticleId IdType="pubmed">27377005</ArticleId></ArticleIdList></Reference><Reference><Citation>Desaphy J.-F., Gramegna G., Altamura C., Dinardo M.M., Imbrici P., George A.L., Jr., Modoni A., Lomonaco M., Conte Camerino D. Functional characterization of ClC-1 mutations from patients affected by recessive myotonia congenita presenting with different clinical phenotypes. Exp. Neurol. 2013;248:530&#x2013;540. doi: 10.1016/j.expneurol.2013.07.018.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.expneurol.2013.07.018</ArticleId><ArticleId IdType="pmc">PMC3781327</ArticleId><ArticleId IdType="pubmed">23933576</ArticleId></ArticleIdList></Reference><Reference><Citation>Altamura C., Mangiatordi G.F., Nicolotti O., Sahbani D., Farinato A., Leonetti F., Carrat&#xf9; M.R., Conte D., Desaphy J.-F., Imbrici P. Mapping ligand-binding pockets in ClC-1 channels through an integrated in silico and experimental approach using anthracene-9-carboxylic acid and niflumic acid. Br. J. Pharmacol. 2018;175:1770&#x2013;1780. doi: 10.1111/bph.14192.</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/bph.14192</ArticleId><ArticleId IdType="pmc">PMC5913395</ArticleId><ArticleId IdType="pubmed">29500929</ArticleId></ArticleIdList></Reference><Reference><Citation>Desaphy J.-F., Farinato A., Altamura C., De Bellis M., Imbrici P., Tarantino N., Caccia C., Melloni E., Padoani G., Vailati S., et al. Safinamide potential in nondystrophic myotonias: Inhibition of skeletal muscle voltage-gated sodium channels and skeletal muscle hyperexcitability in vitro and in vivo. Exp. Neurol. 2020;328:113287. doi: 10.1016/j.expneurol.2020.113287.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.expneurol.2020.113287</ArticleId><ArticleId IdType="pubmed">32205118</ArticleId></ArticleIdList></Reference><Reference><Citation>Camerino G.M., Fonzino A., Conte E., De Bellis M., Mele A., Liantonio A., Tricarico D., Tarantino N., Dobrowolny G., Musar&#xf2; A., et al. Elucidating the Contribution of Skeletal Muscle Ion Channels to Amyotrophic Lateral Sclerosis in search of new therapeutic options. Sci. Rep. 2019;9:3185. doi: 10.1038/s41598-019-39676-3.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41598-019-39676-3</ArticleId><ArticleId IdType="pmc">PMC6395744</ArticleId><ArticleId IdType="pubmed">30816241</ArticleId></ArticleIdList></Reference><Reference><Citation>Pierno S., Desaphy J.F., Liantonio A., De Bellis M., Bianco G., De Luca A., Frigeri A., Nicchia G.P., Svelto M., L&#xe9;oty C., et al. Change of chloride ion channel conductance is an early event of slow-to-fast fibre type transition during unloading-induced muscle disuse. Brain. 2002;125:1510&#x2013;1521. doi: 10.1093/brain/awf162.</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/brain/awf162</ArticleId><ArticleId IdType="pubmed">12077001</ArticleId></ArticleIdList></Reference><Reference><Citation>De Luca A., Pierno S., Conte Camerino D. Electrical properties of diaphragm and EDL muscles during the life of dystrophic mice. Am. J. Physiol. 1997;272:C333&#x2013;C340. doi: 10.1152/ajpcell.1997.272.1.C333.</Citation><ArticleIdList><ArticleId IdType="doi">10.1152/ajpcell.1997.272.1.C333</ArticleId><ArticleId IdType="pubmed">9038840</ArticleId></ArticleIdList></Reference><Reference><Citation>Dobrowolny G., Martini M., Scicchitano B.M., Romanello V., Boncompagni S., Nicoletti C., Pietrangelo L., De Panfilis S., Catizone A., Bouch&#xe8; M., et al. Muscle expression of SOD1G93A triggers the dismantlement of neuromuscular junction via PKC-Theta. Antioxid. Redox Signal. 2018;28:1105&#x2013;1119. doi: 10.1089/ars.2017.7054.</Citation><ArticleIdList><ArticleId IdType="doi">10.1089/ars.2017.7054</ArticleId><ArticleId IdType="pubmed">28931313</ArticleId></ArticleIdList></Reference><Reference><Citation>Lanuza M.A., Just-Borr&#xe0;s L., Hurtado E., Cilleros-Ma&#xf1;&#xe9; V., Tom&#xe0;s M., Garcia N., Tom&#xe0;s J. The impact of kinases in Amyotrophic Lateral Sclerosis at the neuromuscular synapse: Insights into BDNF/TrkB and PKC signaling. Cells. 2019;8:1578. doi: 10.3390/cells8121578.</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/cells8121578</ArticleId><ArticleId IdType="pmc">PMC6953086</ArticleId><ArticleId IdType="pubmed">31817487</ArticleId></ArticleIdList></Reference><Reference><Citation>Reza M.M., Subramaniyam N., Sim C.M., Ge X., Sathiakumar D., McFarlane C., Sharma M., Kambadur R. Irisin is a pro-myogenic factor that induces skeletal muscle hypertrophy and rescues denervation-induced atrophy. Nat. Commun. 2017;8:1104. doi: 10.1038/s41467-017-01131-0.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41467-017-01131-0</ArticleId><ArticleId IdType="pmc">PMC5653663</ArticleId><ArticleId IdType="pubmed">29062100</ArticleId></ArticleIdList></Reference><Reference><Citation>Kablar B., Rudnicki M.A. Development in the absence of skeletal muscle results in the sequential ablation of motor neurons from the spinal cord to the brain. Dev. Biol. 1999;208:93&#x2013;109. doi: 10.1006/dbio.1998.9184.</Citation><ArticleIdList><ArticleId IdType="doi">10.1006/dbio.1998.9184</ArticleId><ArticleId IdType="pubmed">10075844</ArticleId></ArticleIdList></Reference><Reference><Citation>Lino M.M., Schneider C., Caroni P. Accumulation of SOD1 mutants in postnatal motoneurons does not cause motoneuron pathology or motoneuron disease. J. Neurosci. 2002;22:4825&#x2013;4832. doi: 10.1523/JNEUROSCI.22-12-04825.2002.</Citation><ArticleIdList><ArticleId IdType="doi">10.1523/JNEUROSCI.22-12-04825.2002</ArticleId><ArticleId IdType="pmc">PMC6757755</ArticleId><ArticleId IdType="pubmed">12077179</ArticleId></ArticleIdList></Reference><Reference><Citation>Pramatarova A., Lagani&#xe8;re J., Roussel J., Brisebois K., Rouleau G.A. Neuron-specific expression of mutant superoxide dismutase 1 in transgenic mice does not lead to motor impairment. J. Neurosci. 2001;21:3369&#x2013;3374. doi: 10.1523/JNEUROSCI.21-10-03369.2001.</Citation><ArticleIdList><ArticleId IdType="doi">10.1523/JNEUROSCI.21-10-03369.2001</ArticleId><ArticleId IdType="pmc">PMC6762496</ArticleId><ArticleId IdType="pubmed">11331366</ArticleId></ArticleIdList></Reference><Reference><Citation>Yamanaka K., Boillee S., Roberts E.A., Garcia M.L., McAlonis-Downes M., Mikse O.R., Cleveland D.W., Goldstein L.S. Mutant SOD1 in cell types other than motor neurons and oligodendrocytes accelerates onset of disease in ALS mice. Proc. Natl. Acad. Sci. USA. 2008;105:7594&#x2013;7599. doi: 10.1073/pnas.0802556105.</Citation><ArticleIdList><ArticleId IdType="doi">10.1073/pnas.0802556105</ArticleId><ArticleId IdType="pmc">PMC2396671</ArticleId><ArticleId IdType="pubmed">18492803</ArticleId></ArticleIdList></Reference><Reference><Citation>Bensimon G., Lacomblez L., Meininger V. A controlled trial of riluzole in amyotrophic lateral sclerosis. ALS/Riluzole Study Group. N. Engl. J. Med. 1994;330:585&#x2013;591. doi: 10.1056/NEJM199403033300901.</Citation><ArticleIdList><ArticleId IdType="doi">10.1056/NEJM199403033300901</ArticleId><ArticleId IdType="pubmed">8302340</ArticleId></ArticleIdList></Reference><Reference><Citation>De Bellis M., Carbonara R., Roussel J., Farinato A., Massari A., Pierno S., Muraglia M., Corbo F., Franchini C., Carrat&#xf9; M.R., et al. Increased sodium channel use-dependent inhibition by a new potent analogue of tocainide greatly enhances in vivo antimyotonic activity. Neuropharmacology. 2017;113:206&#x2013;216. doi: 10.1016/j.neuropharm.2016.10.013.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.neuropharm.2016.10.013</ArticleId><ArticleId IdType="pmc">PMC5154332</ArticleId><ArticleId IdType="pubmed">27743929</ArticleId></ArticleIdList></Reference><Reference><Citation>Farinato A., Altamura C., Desaphy J.-F. Effects of benzothiazolamines on voltage-gated sodium channels. Handb. Exp. Pharmacol. 2018;246:233&#x2013;250.</Citation><ArticleIdList><ArticleId IdType="pubmed">28939972</ArticleId></ArticleIdList></Reference><Reference><Citation>Al-Chalabi A., Andersen P.M., Chandran S., Chio A., Corcia P., Couratier P., Danielsson O., de Carvalho M., Desnuelle C., Grehl T., et al. July 2017 ENCALS statement on edaravone. Amyotroph. Lateral Scler. Frontotemporal. Degener. 2017;18:471&#x2013;474. doi: 10.1080/21678421.2017.1369125.</Citation><ArticleIdList><ArticleId IdType="doi">10.1080/21678421.2017.1369125</ArticleId><ArticleId IdType="pubmed">28975816</ArticleId></ArticleIdList></Reference><Reference><Citation>Trias E., King P.H., Si Y., Kwon Y., Varela V., Ibarburu S., Kovacs M., Moura I.C., Beckman J.S., Hermine O., et al. Mast cells and neutrophils mediate peripheral motor pathway degeneration in ALS. JCI Insight. 2018;3:e123249. doi: 10.1172/jci.insight.123249.</Citation><ArticleIdList><ArticleId IdType="doi">10.1172/jci.insight.123249</ArticleId><ArticleId IdType="pmc">PMC6237484</ArticleId><ArticleId IdType="pubmed">30282815</ArticleId></ArticleIdList></Reference><Reference><Citation>Lepore E., Casola I., Dobrowolny G., Musar&#xf2; A. Neuromuscular junction as an entity of nerve-muscle communication. Cells. 2019;8:906. doi: 10.3390/cells8080906.</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/cells8080906</ArticleId><ArticleId IdType="pmc">PMC6721719</ArticleId><ArticleId IdType="pubmed">31426366</ArticleId></ArticleIdList></Reference><Reference><Citation>Chung M.J., Suh Y.L. Ultrastructural changes of mitochondria in the skeletal muscle of patients with amyotrophic lateral sclerosis. Ultrastruct. Pathol. 2002;26:3&#x2013;7. doi: 10.1080/01913120252934260.</Citation><ArticleIdList><ArticleId IdType="doi">10.1080/01913120252934260</ArticleId><ArticleId IdType="pubmed">12028652</ArticleId></ArticleIdList></Reference><Reference><Citation>Xiao Y., Karam C., Yi J., Zhang L., Li X., Yoon D., Wang H., Dhakal K., Ramlow P., Yu T., et al. ROS-related mitochondrial dysfunction in skeletal muscle of an ALS mouse model during the disease progression. Pharmacol. Res. 2018;138:25&#x2013;36. doi: 10.1016/j.phrs.2018.09.008.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.phrs.2018.09.008</ArticleId><ArticleId IdType="pmc">PMC6263743</ArticleId><ArticleId IdType="pubmed">30236524</ArticleId></ArticleIdList></Reference><Reference><Citation>Zorov D.B., Juhaszova M., Sollott S.J. Mitochondrial reactive oxygen species (ROS) and ROS-induced ROS release. Physiol. Rev. 2014;94:909&#x2013;950. doi: 10.1152/physrev.00026.2013.</Citation><ArticleIdList><ArticleId IdType="doi">10.1152/physrev.00026.2013</ArticleId><ArticleId IdType="pmc">PMC4101632</ArticleId><ArticleId IdType="pubmed">24987008</ArticleId></ArticleIdList></Reference><Reference><Citation>Bertini E., Dessaud E., Mercuri E., Muntoni F., Kirschner J., Reid C., Lusakowska A., Comi G.P., Cuisset J.M., Abitbol J.L., et al. Olesoxime SMA Phase 2 Study Investigators. Safety and efficacy of olesoxime in patients with type 2 or non-ambulatory type 3 spinal muscular atrophy: A randomised, double-blind, placebo-controlled phase 2 trial. Lancet Neurol. 2017;16:513&#x2013;522. doi: 10.1016/S1474-4422(17)30085-6.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S1474-4422(17)30085-6</ArticleId><ArticleId IdType="pubmed">28460889</ArticleId></ArticleIdList></Reference><Reference><Citation>Cudkowicz M.E., van den Berg L.H., Shefner J.M., Mitsumoto H., Mora J.S., Ludolph A., Hardiman O., Bozik M.E., Ingersoll E.W., Archibald D., et al. Dexpramipexole versus placebo for patients with amyotrophic lateral sclerosis (EMPOWER): A randomised, double-blind, phase 3 trial. Lancet Neurol. 2013;12:1059&#x2013;1067. doi: 10.1016/S1474-4422(13)70221-7.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S1474-4422(13)70221-7</ArticleId><ArticleId IdType="pubmed">24067398</ArticleId></ArticleIdList></Reference><Reference><Citation>Rosenfeld J., King R.M., Jackson C.E., Bedlack R.S., Barohn R.J., Dick A., Phillips L.H., Chapin J., Gelinas D.F., Lou J.S. Creatine monohydrate in ALS: Effects on strength, fatigue, respiratory status and ALSFRS. Amyotroph. Lateral Scler. 2008;9:266&#x2013;272. doi: 10.1080/17482960802028890.</Citation><ArticleIdList><ArticleId IdType="doi">10.1080/17482960802028890</ArticleId><ArticleId IdType="pmc">PMC2631354</ArticleId><ArticleId IdType="pubmed">18608103</ArticleId></ArticleIdList></Reference><Reference><Citation>Cestra G., Rossi S., Di Salvio M., Cozzolino M. Control of mRNA translation in ALS proteinopathy. Front. Mol. Neurosci. 2017;10:85. doi: 10.3389/fnmol.2017.00085.</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fnmol.2017.00085</ArticleId><ArticleId IdType="pmc">PMC5362592</ArticleId><ArticleId IdType="pubmed">28386218</ArticleId></ArticleIdList></Reference><Reference><Citation>Crippa V., Boncoraglio A., Galbiati M., Aggarwal T., Rusmini P., Giorgetti E., Cristofani R., Carra S., Pennuto M., Poletti A. Differential autophagy power in the spinal cord and muscle of transgenic ALS mice. Front. Cell Neurosci. 2013;7:234. doi: 10.3389/fncel.2013.00234.</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fncel.2013.00234</ArticleId><ArticleId IdType="pmc">PMC3840302</ArticleId><ArticleId IdType="pubmed">24324403</ArticleId></ArticleIdList></Reference><Reference><Citation>Mandrioli J., D&#x2019;Amico R., Zucchi E., Gessani A., Fini N., Fasano A., Caponnetto C., Chi&#xf2; A., Dalla Bella E., Lunetta C., et al. Rapamycin treatment for amyotrophic lateral sclerosis: Protocol for a phase II randomized, double-blind, placebo-controlled, multicenter, clinical trial (RAP-ALS trial) Medicine. 2018;97:e11119. doi: 10.1097/MD.0000000000011119.</Citation><ArticleIdList><ArticleId IdType="doi">10.1097/MD.0000000000011119</ArticleId><ArticleId IdType="pmc">PMC6024184</ArticleId><ArticleId IdType="pubmed">29901635</ArticleId></ArticleIdList></Reference><Reference><Citation>Pierno S., Camerino G.M., Cannone M., Liantonio A., De Bellis M., Digennaro C., Gramegna G., De Luca A., Germinario E., Danieli-Betto D., et al. Paracrine effects of IGF-1 overexpression on the functional decline due to skeletal muscle disuse: Molecular and functional evaluation in hindlimb unloaded MLC/mIgf-1 transgenic mice. PLoS ONE. 2013;8:e65167. doi: 10.1371/journal.pone.0065167.</Citation><ArticleIdList><ArticleId IdType="doi">10.1371/journal.pone.0065167</ArticleId><ArticleId IdType="pmc">PMC3670938</ArticleId><ArticleId IdType="pubmed">23755187</ArticleId></ArticleIdList></Reference><Reference><Citation>Borasio G.D., Robberecht W., Leigh P.N., Emile J., Guiloff R.J., Jerusalem F., Silani V., Vos P.E., Wokke J.H., Dobbins T. A placebo-controlled trial of insulin-like growth factor-I in amyotrophic lateral sclerosis. European ALS/IGF-I Study Group. Neurology. 1998;51:583&#x2013;586. doi: 10.1212/WNL.51.2.583.</Citation><ArticleIdList><ArticleId IdType="doi">10.1212/WNL.51.2.583</ArticleId><ArticleId IdType="pubmed">9710040</ArticleId></ArticleIdList></Reference><Reference><Citation>Sorenson E.J., Windbank A.J., Mandrekar J.N., Bamlet W.R., Appel S.H., Armon C., Barkhaus P.E., Bosch P., Boylan K., David W.S., et al. Subcutaneous IGF-1 is not beneficial in 2-year ALS trial. Neurology. 2008;71:1770&#x2013;1775. doi: 10.1212/01.wnl.0000335970.78664.36.</Citation><ArticleIdList><ArticleId IdType="doi">10.1212/01.wnl.0000335970.78664.36</ArticleId><ArticleId IdType="pmc">PMC2617770</ArticleId><ArticleId IdType="pubmed">19029516</ArticleId></ArticleIdList></Reference><Reference><Citation>Paganoni S., Macklin E.A., Hendrix S., Berry J.D., Elliott M.A., Maiser S., Karam C., Caress J.B., Owegi M.A., Quick A., et al. Trial of sodium phenylbutyrate-taurursodiol for Amyotrophic Lateral Sclerosis. N. Engl. J. Med. 2020;383:919&#x2013;930. doi: 10.1056/NEJMoa1916945.</Citation><ArticleIdList><ArticleId IdType="doi">10.1056/NEJMoa1916945</ArticleId><ArticleId IdType="pubmed">32877582</ArticleId></ArticleIdList></Reference><Reference><Citation>Palma E., Reyes-Ruiz J.M., Lopergolo D., Roseti C., Bertollini C., Ruffolo G., Cifelli P., Onesti E., Limatola C., Miledi R., et al. Acetylcholine receptors from human muscle as pharmacological targets for ALS therapy. Proc. Natl. Acad. Sci. USA. 2016;113:3060&#x2013;3065. doi: 10.1073/pnas.1600251113.</Citation><ArticleIdList><ArticleId IdType="doi">10.1073/pnas.1600251113</ArticleId><ArticleId IdType="pmc">PMC4801305</ArticleId><ArticleId IdType="pubmed">26929355</ArticleId></ArticleIdList></Reference><Reference><Citation>Szczudlik A., Tomik B., S&#x142;owik A., Kasprzyk K. Ocena skuteczno&#x15b;ci pimozydu u chorych ze stwardnieniem bocznym zanikowym. Doniesienie wstepne [Assessment of the efficacy of treatment with pimozide in patients with amyotrophic lateral sclerosis. Introductory notes] Neurol. Neurochir. Pol. 1998;32:821&#x2013;829.</Citation><ArticleIdList><ArticleId IdType="pubmed">9864711</ArticleId></ArticleIdList></Reference><Reference><Citation>Patten S.A., Aggad D., Martinez J., Tremblay E., Petrillo J., Armstrong G.A., La Fontaine A., Maios C., Liao M., Ciura S., et al. Neuroleptics as therapeutic compounds stabilizing neuromuscular transmission in amyotrophic lateral sclerosis. JCI Insight. 2017;2:e97152. doi: 10.1172/jci.insight.97152.</Citation><ArticleIdList><ArticleId IdType="doi">10.1172/jci.insight.97152</ArticleId><ArticleId IdType="pmc">PMC5752378</ArticleId><ArticleId IdType="pubmed">29202456</ArticleId></ArticleIdList></Reference><Reference><Citation>Bose P., Tremblay E., Maios C., Narasimhan V., Armstrong G.A.B., Liao M., Parker J.A., Robitaille R., Wen X.Y., Barden C., et al. The novel small molecule TRVA242 stabilizes neuromuscular junction defects in multiple animal models of Amyotrophic Lateral Sclerosis. Neurotherapeutics. 2019;16:1149&#x2013;1166. doi: 10.1007/s13311-019-00765-w. Erratum in Neurotherapeutics 2021, 18, 2128.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s13311-019-00765-w</ArticleId><ArticleId IdType="pmc">PMC6985319</ArticleId><ArticleId IdType="pubmed">31342410</ArticleId></ArticleIdList></Reference><Reference><Citation>Carreras I., Yuruker S., Aytan N., Hossain L., Choi J.K., Jenkins B.G., Kowall N.W., Dedeoglu A. Moderate exercise delays the motor performance decline in a transgenic model of ALS. Brain Res. 2010;1313:192&#x2013;201. doi: 10.1016/j.brainres.2009.11.051.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.brainres.2009.11.051</ArticleId><ArticleId IdType="pmc">PMC2892864</ArticleId><ArticleId IdType="pubmed">19968977</ArticleId></ArticleIdList></Reference><Reference><Citation>Smith R.A., Miller T.M., Yamanaka K., Monia B.P., Condon T.P., Hung G., Lobsiger C.S., Ward C.M., McAlonis-Downes M., Wei H., et al. Antisense oligonucleotide therapy for neurodegenerative disease. J. Clin. Invest. 2006;116:2290&#x2013;2296. doi: 10.1172/JCI25424.</Citation><ArticleIdList><ArticleId IdType="doi">10.1172/JCI25424</ArticleId><ArticleId IdType="pmc">PMC1518790</ArticleId><ArticleId IdType="pubmed">16878173</ArticleId></ArticleIdList></Reference><Reference><Citation>Ly C.V., Miller T.M. Emerging antisense oligonucleotide and viral therapies for amyotrophic lateral sclerosis. Curr. Opin. Neurol. 2018;31:648&#x2013;654. doi: 10.1097/WCO.0000000000000594.</Citation><ArticleIdList><ArticleId IdType="doi">10.1097/WCO.0000000000000594</ArticleId><ArticleId IdType="pmc">PMC7291817</ArticleId><ArticleId IdType="pubmed">30028737</ArticleId></ArticleIdList></Reference><Reference><Citation>Biferi M.G., Cohen-Tannoudji M., Cappelletto A., Giroux B., Roda M., Astord S., Marais T., Bos C., Voit T., Ferry A., et al. A New AAV10-U7-Mediated Gene Therapy Prolongs Survival and Restores Function in an ALS Mouse Model. Mol. Ther. 2017;25:2038&#x2013;2052. doi: 10.1016/j.ymthe.2017.05.017.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.ymthe.2017.05.017</ArticleId><ArticleId IdType="pmc">PMC5589057</ArticleId><ArticleId IdType="pubmed">28663100</ArticleId></ArticleIdList></Reference><Reference><Citation>Jiang J., Zhu Q., Gendron T.F., Saberi S., McAlonis-Downes M., Seelman A., Stauffer J.E., Jafar-Nejad P., Drenner K., Schulte D., et al. Gain of toxicity from ALS/FTD-linked repeat expansions in C9ORF72 is alleviated by antisense oligonucleotides targeting GGGGCC-containing RNAs. Neuron. 2016;90:535&#x2013;550. doi: 10.1016/j.neuron.2016.04.006.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.neuron.2016.04.006</ArticleId><ArticleId IdType="pmc">PMC4860075</ArticleId><ArticleId IdType="pubmed">27112497</ArticleId></ArticleIdList></Reference><Reference><Citation>Miller T., Cudkowicz M., Shaw P.J., Andersen P.M., Atassi N., Bucelli R.C., Genge A., Glass J., Ladha S., Ludolph A.L., et al. Phase 1&#x2013;2 Trial of Antisense Oligonucleotide Tofersen for SOD1 ALS. N. Engl. J. Med. 2020;383:109&#x2013;119. doi: 10.1056/NEJMoa2003715.</Citation><ArticleIdList><ArticleId IdType="doi">10.1056/NEJMoa2003715</ArticleId><ArticleId IdType="pubmed">32640130</ArticleId></ArticleIdList></Reference><Reference><Citation>Lange D.J., Shahbazi M., Silani V., Ludolph A.C., Weishaupt J.H., Ajroud-Driss S., Fields K.G., Remanan R., Appel S.H., Morelli C., et al. Pyrimethamine significantly lowers cerebrospinal fluid Cu/Zn superoxide dismutase in amyotrophic lateral sclerosis patients with SOD1 mutations. Ann. Neurol. 2017;81:837&#x2013;848. doi: 10.1002/ana.24950.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/ana.24950</ArticleId><ArticleId IdType="pmc">PMC5518287</ArticleId><ArticleId IdType="pubmed">28480639</ArticleId></ArticleIdList></Reference><Reference><Citation>Mazzini L., Mareschi K., Ferrero I., Vassallo E., Oliveri G., Nasuelli N., Oggioni G.D., Testa L., Fagioli F. Stem cell treatment in amyotrophic lateral sclerosis. J. Neurol. Sci. 2008;265:78&#x2013;83. doi: 10.1016/j.jns.2007.05.016.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.jns.2007.05.016</ArticleId><ArticleId IdType="pubmed">17582439</ArticleId></ArticleIdList></Reference><Reference><Citation>Keeler A.M., Zieger M., Semple C., Pucci L., Veinbachs A., Brown R.H., Jr., Mueller C., ElMallah M.K. Intralingual and Intrapleural AAV Gene Therapy Prolongs Survival in a SOD1 ALS Mouse Model. Mol. Ther. Methods Clin. Dev. 2019;17:246&#x2013;257. doi: 10.1016/j.omtm.2019.12.007.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.omtm.2019.12.007</ArticleId><ArticleId IdType="pmc">PMC6962641</ArticleId><ArticleId IdType="pubmed">31970202</ArticleId></ArticleIdList></Reference><Reference><Citation>Lind L.A., Andel E.M., McCall A.L., Dhindsa J.S., Johnson K.A., Stricklin O.E., Mueller C., ElMallah M.K., Lever T.E., Nichols N.L. Intralingual Administration of AAVrh10-miRSOD1 Improves Respiratory But Not Swallowing Function in a Superoxide Dismutase-1 Mouse Model of Amyotrophic Lateral Sclerosis. Hum. Gene Ther. 2020;31:828&#x2013;838. doi: 10.1089/hum.2020.065.</Citation><ArticleIdList><ArticleId IdType="doi">10.1089/hum.2020.065</ArticleId><ArticleId IdType="pmc">PMC7462029</ArticleId><ArticleId IdType="pubmed">32498636</ArticleId></ArticleIdList></Reference><Reference><Citation>Mueller C., Berry J.D., McKenna-Yasek D.M., Gernoux G., Owegi M.A., Pothier L.M., Douthwright C.L., Gelevski D., Luppino S.D., Blackwood M., et al. SOD1 Suppression with Adeno-Associated Virus and MicroRNA in Familial ALS. N. Engl. J. Med. 2020;383:151&#x2013;158. doi: 10.1056/NEJMoa2005056.</Citation><ArticleIdList><ArticleId IdType="doi">10.1056/NEJMoa2005056</ArticleId><ArticleId IdType="pubmed">32640133</ArticleId></ArticleIdList></Reference><Reference><Citation>Devos D., Moreau C., Kyheng M., Gar&#xe7;on G., Rolland A.S., Blasco H., Gel&#xe9; P., Timoth&#xe9;e Lenglet T., Veyrat-Durebex C., Corcia P., et al. A ferroptosis-based panel of prognostic biomarkers for Amyotrophic Lateral Sclerosis. Sci. Rep. 2019;9:2918. doi: 10.1038/s41598-019-39739-5.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41598-019-39739-5</ArticleId><ArticleId IdType="pmc">PMC6393674</ArticleId><ArticleId IdType="pubmed">30814647</ArticleId></ArticleIdList></Reference><Reference><Citation>Kaufmann P., Thompson J.L., Levy G., Buchsbaum R., Shefner J., Krivickas L.S., Katz J., Rollins Y., Barohn R.J., Jackson C.E., et al. Phase II trial of CoQ10 for ALS finds insufficient evidence to justify phase III. Ann. Neurol. 2009;66:235&#x2013;244. doi: 10.1002/ana.21743.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/ana.21743</ArticleId><ArticleId IdType="pmc">PMC2854625</ArticleId><ArticleId IdType="pubmed">19743457</ArticleId></ArticleIdList></Reference><Reference><Citation>Sacc&#xe0; F., Quarantelli M., Rinaldi C., Tucci T., Piro R., Perrotta G., Carotenuto B., Marsili A., Palma V., De Michele G., et al. A randomized controlled clinical trial of growth hormone in amyotrophic lateral sclerosis: Clinical, neuroimaging, and hormonal results. J. Neurol. 2012;259:132&#x2013;138. doi: 10.1007/s00415-011-6146-2.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s00415-011-6146-2</ArticleId><ArticleId IdType="pubmed">21706151</ArticleId></ArticleIdList></Reference><Reference><Citation>Andrews J.A., Cudkowicz M.E., Hardiman O., Meng L., Bian A., Lee J., Wolff A.A., Malik F.I., Shefner J.M. VITALITY-ALS, a phase III trial of tirasemtiv, a selective fast skeletal muscle troponin activator, as a potential treatment for patients with amyotrophic lateral sclerosis: Study design and baseline characteristics. Amyotroph. Lateral Scler. Frontotemporal. Degener. 2018;19:259&#x2013;266. doi: 10.1080/21678421.2018.1426770. Erratum in Amyotroph. Lateral Scler. Frontotemporal. Degener. 2018, 19, 321.</Citation><ArticleIdList><ArticleId IdType="doi">10.1080/21678421.2018.1426770</ArticleId><ArticleId IdType="pubmed">29402141</ArticleId></ArticleIdList></Reference><Reference><Citation>Shefner J.M., Andrews J.A., Genge A., Jackson C., Lechtzin N., Miller T.M., Cockroft B.M., Meng L., Wie J., Wolff A.A., et al. A Phase 2, Double-Blind, Randomized, Dose-Ranging Trial Of Reldesemtiv In Patients With ALS. Amyotroph. Lateral Scler. Frontotemporal. Degener. 2021;22:287&#x2013;299. doi: 10.1080/21678421.2020.1822410.</Citation><ArticleIdList><ArticleId IdType="doi">10.1080/21678421.2020.1822410</ArticleId><ArticleId IdType="pmc">PMC8117790</ArticleId><ArticleId IdType="pubmed">32969758</ArticleId></ArticleIdList></Reference><Reference><Citation>Wainger B.J., Macklin E.A., Vucic S., McIlduff C.E., Paganoni S., Maragakis N.J., Bedlack R., Goyal N.A., Rutkove S.B., Lange D.J., et al. Effect of Ezogabine on Cortical and Spinal Motor Neuron Excitability in Amyotrophic Lateral Sclerosis: A Randomized Clinical Trial. JAMA Neurol. 2021;78:186&#x2013;196. doi: 10.1001/jamaneurol.2020.4300.</Citation><ArticleIdList><ArticleId IdType="doi">10.1001/jamaneurol.2020.4300</ArticleId><ArticleId IdType="pmc">PMC7684515</ArticleId><ArticleId IdType="pubmed">33226425</ArticleId></ArticleIdList></Reference><Reference><Citation>Oskarsson B., Moore D., Mozaffar T., Ravits J., Wiedau-Pazos M., Parziale N., Joyce N.C., Mandeville R., Goyal N., Cudkowicz M.E., et al. Mexiletine for muscle cramps in amyotrophic lateral sclerosis: A randomized, double-blind crossover trial. Muscle Nerve. 2018;58:42&#x2013;48. doi: 10.1002/mus.26117.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/mus.26117</ArticleId><ArticleId IdType="pmc">PMC6126993</ArticleId><ArticleId IdType="pubmed">29510461</ArticleId></ArticleIdList></Reference><Reference><Citation>Cudkowicz M., Genge A., Maragakis N., Petri S., van den Berg L., Aho V.V., Sarapohja T., Kuoppam&#xe4;ki M., Garratt C., Al-Chalabi A., et al. Safety and efficacy of oral levosimendan in people with amyotrophic lateral sclerosis (the REFALS study): A randomised, double-blind, placebo-controlled phase 3 trial. Lancet Neurol. 2021;20:821&#x2013;831. doi: 10.1016/S1474-4422(21)00242-8.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S1474-4422(21)00242-8</ArticleId><ArticleId IdType="pubmed">34536404</ArticleId></ArticleIdList></Reference><Reference><Citation>Mandrioli J., Crippa V., Cereda C., Bonetto V., Zucchi E., Gessani A., Ceroni M., Chio A., D&#x2019;Amico R., Monsurr&#xf2; M.R., et al. Proteostasis and ALS: Protocol for a phase II, randomised, double-blind, placebo-controlled, multicentre clinical trial for colchicine in ALS (Co-ALS) BMJ Open. 2019;9:e028486. doi: 10.1136/bmjopen-2018-028486.</Citation><ArticleIdList><ArticleId IdType="doi">10.1136/bmjopen-2018-028486</ArticleId><ArticleId IdType="pmc">PMC6549675</ArticleId><ArticleId IdType="pubmed">31152038</ArticleId></ArticleIdList></Reference><Reference><Citation>De la Rubia J.E., Drehmer E., Platero J.L., Benlloch M., Caplliure-Llopis J., Villaron-Casales C., de Bernardo N., Alarc&#xd3;n J., Fuente C., Carrera S., et al. Efficacy and tolerability of EH301 for amyotrophic lateral sclerosis: A randomized, double-blind, placebo-controlled human pilot study. Amyotroph. Lateral Scler. Frontotemporal. Degener. 2019;20:115&#x2013;122. doi: 10.1080/21678421.2018.1536152.</Citation><ArticleIdList><ArticleId IdType="doi">10.1080/21678421.2018.1536152</ArticleId><ArticleId IdType="pubmed">30668199</ArticleId></ArticleIdList></Reference><Reference><Citation>Meininger V., Genge A., van den Berg L.H., Robberecht W., Ludolph A., Chio A., Kim S.H., Leigh P.N., Kiernan M.C., Shefner J.M., et al. Safety and efficacy of ozanezumab in patients with amyotrophic lateral sclerosis: A randomised, double-blind, placebo-controlled, phase 2 trial. Lancet Neurol. 2017;16:208&#x2013;216. doi: 10.1016/S1474-4422(16)30399-4.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S1474-4422(16)30399-4</ArticleId><ArticleId IdType="pubmed">28139349</ArticleId></ArticleIdList></Reference><Reference><Citation>Arrat H., Lukas T.J., Siddique T. ACTH (Acthar Gel) Reduces Toxic SOD1 Protein Linked to Amyotrophic Lateral Sclerosis in Transgenic Mice: A Novel Observation. PLoS ONE. 2015;10:e0125638.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4425507</ArticleId><ArticleId IdType="pubmed">25955410</ArticleId></ArticleIdList></Reference><Reference><Citation>Drory V.E., Goltsman E., Reznik J.G., Mosek A., Korczyn A.D. The value of muscle exercise in patients with amyotrophic lateral sclerosis. J. Neurol. Sci. 2001;191:133&#x2013;137. doi: 10.1016/S0022-510X(01)00610-4.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S0022-510X(01)00610-4</ArticleId><ArticleId IdType="pubmed">11677004</ArticleId></ArticleIdList></Reference><Reference><Citation>Bello-Haas V.D., Florence J.M., Kloos A.D., Scheirbecker J., Lopate G., Hayes S.M., Pioro E.P., Mitsumoto H. A randomized controlled trial of resistance exercise in individuals with ALS. Neurology. 2007;68:2003&#x2013;2007. doi: 10.1212/01.wnl.0000264418.92308.a4.</Citation><ArticleIdList><ArticleId IdType="doi">10.1212/01.wnl.0000264418.92308.a4</ArticleId><ArticleId IdType="pubmed">17548549</ArticleId></ArticleIdList></Reference><Reference><Citation>Manzano R., Toivonen J.M., Moreno-Mart&#xed;nez L., de la Torre M., Moreno-Garc&#xed;a L., L&#xf3;pez-Royo T., Molina N., Zaragoza P., Calvo A.C., Osta R. What skeletal muscle has to say in amyotrophic lateral sclerosis: Implications for therapy. Br. J. Pharmacol. 2021;178:1279&#x2013;1297. doi: 10.1111/bph.15276.</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/bph.15276</ArticleId><ArticleId IdType="pubmed">32986860</ArticleId></ArticleIdList></Reference><Reference><Citation>Suzuki M., McHugh J., Tork C., Shelley B., Hayes A., Bellantuono I., Aebischer P., Svendsen C.N. Direct muscle delivery of GDNF with human mesenchymal stem cells improves motor neuron survival and function in a rat model of familial ALS. Mol. Ther. 2008;16:2002&#x2013;2010. doi: 10.1038/mt.2008.197.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/mt.2008.197</ArticleId><ArticleId IdType="pmc">PMC2678899</ArticleId><ArticleId IdType="pubmed">18797452</ArticleId></ArticleIdList></Reference><Reference><Citation>Li W., Brakefield D., Pan Y., Hunter D., Myckatyn T.M., Parsadanian A. Muscle-derived but not centrally derived transgene GDNF is neuroprotective in G93A-SOD1 mouse model of ALS. Exp. Neurol. 2007;203:457&#x2013;471. doi: 10.1016/j.expneurol.2006.08.028.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.expneurol.2006.08.028</ArticleId><ArticleId IdType="pubmed">17034790</ArticleId></ArticleIdList></Reference><Reference><Citation>Shim J.W., Madsen J.R. VEGF signaling in neurological disorders. Int. J. Mol. Sci. 2018;19:275. doi: 10.3390/ijms19010275.</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/ijms19010275</ArticleId><ArticleId IdType="pmc">PMC5796221</ArticleId><ArticleId IdType="pubmed">29342116</ArticleId></ArticleIdList></Reference><Reference><Citation>Azzouz M., Ralph G.S., Storkebaum E., Walmsley L.E., Mitrophanous K.A., Kingsman S.M., Carmellet P., Mazarakis N.D. VEGF delivery with retrogradely transported lentivector prolongs survival in a mouse ALS model. Nature. 2004;429:413&#x2013;417. doi: 10.1038/nature02544.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/nature02544</ArticleId><ArticleId IdType="pubmed">15164063</ArticleId></ArticleIdList></Reference><Reference><Citation>Ngo S.T., Cole R.N., Sunn N., Phillips W.D., Noakes P.G. Neuregulin-1 potentiates agrin-induced acetylcholine: Receptor clustering through muscle-specific kinase: Phosphorylation. J. Cell Sci. 2012;125:1531&#x2013;1543. doi: 10.1242/jcs.095109.</Citation><ArticleIdList><ArticleId IdType="doi">10.1242/jcs.095109</ArticleId><ArticleId IdType="pubmed">22328506</ArticleId></ArticleIdList></Reference><Reference><Citation>M&#xf2;dol-Caballero G., Herrando-Grabulosa M., Garc&#xed;a-Lareu B., Solanes N., Verd&#xe9;s S., Osta R., Francos-Quijorna I., L&#xf3;pez-Vales R., Calvo A.C., Bosch A., et al. Gene therapy for overexpressing Neuregulin 1 type I in skeletal muscles promotes functional improvement in the SOD1G93A ALS mice. Neurobiol. Dis. 2020;137:104793. doi: 10.1016/j.nbd.2020.104793.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.nbd.2020.104793</ArticleId><ArticleId IdType="pubmed">32032731</ArticleId></ArticleIdList></Reference><Reference><Citation>Zuccaro E., Piol D., Basso M., Pennuto M. Motor Neuron Diseases and Neuroprotective Peptides: A Closer Look to Neurons. Front. Aging Neurosci. 2021;13:723871. doi: 10.3389/fnagi.2021.723871.</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fnagi.2021.723871</ArticleId><ArticleId IdType="pmc">PMC8484953</ArticleId><ArticleId IdType="pubmed">34603008</ArticleId></ArticleIdList></Reference><Reference><Citation>Beal M.F. Neuroprotective effects of creatine. Amino Acids. 2011;40:1305&#x2013;1313. doi: 10.1007/s00726-011-0851-0.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s00726-011-0851-0</ArticleId><ArticleId IdType="pubmed">21448659</ArticleId></ArticleIdList></Reference><Reference><Citation>Cappello V., Vezzoli E., Righi M., Fossati M., Mariotti R., Crespi A., Patruno M., Bentivoglio M., Pietrini G., Francolini M. Analysis of neuromuscular junctions and effects of anabolic steroid administration in the SOD1G93A mouse model of ALS. Mol. Cell Neurosci. 2012;51:12&#x2013;21. doi: 10.1016/j.mcn.2012.07.003.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.mcn.2012.07.003</ArticleId><ArticleId IdType="pubmed">22800606</ArticleId></ArticleIdList></Reference><Reference><Citation>Vergouts M., Marinangeli C., Ingelbrecht C., Genard G., Schakman O., Sternotte A., Calas A.G., Hermans E. Early ALS-type gait abnormalities in AMP-dependent protein kinase-deficient mice suggest a role for this metabolic sensor in early stages of the disease. Metab. Brain Dis. 2015;30:1369&#x2013;1377. doi: 10.1007/s11011-015-9706-9.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s11011-015-9706-9</ArticleId><ArticleId IdType="pubmed">26152932</ArticleId></ArticleIdList></Reference><Reference><Citation>Kj&#xf8;bsted R., Hingst J.R., Fentz J., Foretz M., Sanz M.N., Pehm&#xf8;ller C., Shum M., Marette A., Mounier R., Treebak J.T., et al. AMPK in skeletal muscle function and metabolism. FASEB J. 2018;32:1741&#x2013;1777. doi: 10.1096/fj.201700442R.</Citation><ArticleIdList><ArticleId IdType="doi">10.1096/fj.201700442R</ArticleId><ArticleId IdType="pmc">PMC5945561</ArticleId><ArticleId IdType="pubmed">29242278</ArticleId></ArticleIdList></Reference><Reference><Citation>Mantuano P., Sanarica F., Conte E., Morgese M.G., Capogrosso R.F., Cozzoli A., Fonzino A., Quaranta A., Rolland J.F., De Bellis M., et al. Effect of a long-term treatment with metformin in dystrophic mdx mice: A reconsideration of its potential clinical interest in Duchenne muscular dystrophy. Biochem. Pharmacol. 2018;154:89&#x2013;103. doi: 10.1016/j.bcp.2018.04.022.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.bcp.2018.04.022</ArticleId><ArticleId IdType="pubmed">29684379</ArticleId></ArticleIdList></Reference><Reference><Citation>Rosbash M. Metformin treatment of the C9orf72 ALS/FTD mouse: Almost too good for words. Proc. Natl. Acad. Sci. USA. 2020;117:19627&#x2013;19628. doi: 10.1073/pnas.2012363117.</Citation><ArticleIdList><ArticleId IdType="doi">10.1073/pnas.2012363117</ArticleId><ArticleId IdType="pmc">PMC7443920</ArticleId><ArticleId IdType="pubmed">32727895</ArticleId></ArticleIdList></Reference><Reference><Citation>Scaricamazza S., Salvatori I., Amadio S., Nesci V., Torcinaro A., Giacovazzo G., Primiano A., Gloriani M., Candelise N., Pieroni L., et al. Repurposing of Trimetazidine for Amyotrophic Lateral Sclerosis: A study in SOD1G93A mice. Br. J. Pharmacol. 2021:1&#x2013;21. doi: 10.1111/bph.15738.</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/bph.15738</ArticleId><ArticleId IdType="pubmed">34783031</ArticleId></ArticleIdList></Reference><Reference><Citation>Kantor P.F., Lucien A., Kozak R., Lopaschuk G.D. The antianginal drug trimetazidine shifts cardiac energy metabolism from fatty acid oxidation to glucose oxidation by inhibiting mitochondrial long-chain 3-ketoacyl coenzyme A thiolase. Circ. Res. 2000;86:580&#x2013;588. doi: 10.1161/01.RES.86.5.580.</Citation><ArticleIdList><ArticleId IdType="doi">10.1161/01.RES.86.5.580</ArticleId><ArticleId IdType="pubmed">10720420</ArticleId></ArticleIdList></Reference><Reference><Citation>Fragasso G., Piatti Md P.M., Monti L., Palloshi A., Setola E., Puccetti P., Calori G., Lopaschuk G.D., Margonato A. Short- and long-term beneficial effects of trimetazidine in patients with diabetes and ischemic cardiomyopathy. Am. Heart J. 2003;146:E18. doi: 10.1016/S0002-8703(03)00415-0.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S0002-8703(03)00415-0</ArticleId><ArticleId IdType="pubmed">14597947</ArticleId></ArticleIdList></Reference><Reference><Citation>Belli R., Bonato A., De Angelis L., Mirabilii S., Ricciardi M.R., Tafuri A., Molfino A., Gorini S., Leigheb M., Costelli P., et al. Metabolic Reprogramming Promotes Myogenesis During Aging. Front. Physiol. 2019;10:897. doi: 10.3389/fphys.2019.00897.</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fphys.2019.00897</ArticleId><ArticleId IdType="pmc">PMC6636331</ArticleId><ArticleId IdType="pubmed">31354530</ArticleId></ArticleIdList></Reference><Reference><Citation>Scaricamazza S., Salvatori I., Giacovazzo G., Loeffler J.P., Ren&#xe8; F., Rosina M., Quessada C., Proietti D., Heil C., Rossi S., et al. Skeletal-Muscle Metabolic Reprogramming in ALS-SOD1G93A Mice Predates Disease Onset and Is A Promising Therapeutic Target. iScience. 2020;23:101087. doi: 10.1016/j.isci.2020.101087.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.isci.2020.101087</ArticleId><ArticleId IdType="pmc">PMC7200935</ArticleId><ArticleId IdType="pubmed">32371370</ArticleId></ArticleIdList></Reference><Reference><Citation>Milani M., Mammarella E., Rossi S., Miele C., Lattante S., Sabatelli M., Cozzolino M., D&#x2019;Ambrosi N., Apolloni S. Targeting S100A4 with niclosamide attenuates inflammatory and profibrotic pathways in models of amyotrophic lateral sclerosis. J. Neuroinflammation. 2021;18:132. doi: 10.1186/s12974-021-02184-1.</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/s12974-021-02184-1</ArticleId><ArticleId IdType="pmc">PMC8196441</ArticleId><ArticleId IdType="pubmed">34118929</ArticleId></ArticleIdList></Reference><Reference><Citation>Katsumata R., Ishigaki S., Katsuno M., Kawai K., Sone J., Huang Z., Adachi H., Tanaka F., Urano F., Sobue G. c-Abl inhibition delays motor neuron degeneration in the G93A mouse, an animal model of amyotrophic lateral sclerosis. PLoS ONE. 2012;7:e46185. doi: 10.1371/journal.pone.0046185.</Citation><ArticleIdList><ArticleId IdType="doi">10.1371/journal.pone.0046185</ArticleId><ArticleId IdType="pmc">PMC3458026</ArticleId><ArticleId IdType="pubmed">23049975</ArticleId></ArticleIdList></Reference><Reference><Citation>Mantuano P., Boccanegra B., Conte E., De Bellis M., Cirmi S., Sanarica F., Cappellari O., Arduino I., Cutrignelli A., Lopedota A.A., et al. &#x3b2;-Dystroglycan Restoration and Pathology Progression in the Dystrophic mdx Mouse: Outcome and Implication of a Clinically Oriented Study with a Novel Oral Dasatinib Formulation. Biomolecules. 2021;11:1742. doi: 10.3390/biom11111742.</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/biom11111742</ArticleId><ArticleId IdType="pmc">PMC8615430</ArticleId><ArticleId IdType="pubmed">34827740</ArticleId></ArticleIdList></Reference><Reference><Citation>Vucic S., Nicholson G.A., Kiernan M.C. Cortical hyperexcitability may precede the onset of familial amyotrophic lateral sclerosis. Brain. 2008;131:1540&#x2013;1550. doi: 10.1093/brain/awn071.</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/brain/awn071</ArticleId><ArticleId IdType="pubmed">18469020</ArticleId></ArticleIdList></Reference><Reference><Citation>Roselli F., Caroni P. Modeling neuronal vulnerability in ALS. Neuron. 2014;83:758&#x2013;760. doi: 10.1016/j.neuron.2014.08.010.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.neuron.2014.08.010</ArticleId><ArticleId IdType="pubmed">25144872</ArticleId></ArticleIdList></Reference><Reference><Citation>Fritz E., Izaurieta P., Weiss A., Mir F.R., Rojas P., Gonzalez D., Rojas F., Brown R.H., Jr., Madrid R., van Zundert B. Mutant SOD1-expressing astrocytes release toxic factors that trigger motoneuron death by inducing hyperexcitability. J. Neurophysiol. 2013;109:2803&#x2013;2814. doi: 10.1152/jn.00500.2012.</Citation><ArticleIdList><ArticleId IdType="doi">10.1152/jn.00500.2012</ArticleId><ArticleId IdType="pmc">PMC3680799</ArticleId><ArticleId IdType="pubmed">23486205</ArticleId></ArticleIdList></Reference><Reference><Citation>Ghezzi F., Monni L., Nistri A. Functional up-regulation of the M-current by retigabine contrasts hyperexcitability and excitotoxicity on rat hypoglossal motoneurons. J. Physiol. 2018;596:2611&#x2013;2629. doi: 10.1113/JP275906.</Citation><ArticleIdList><ArticleId IdType="doi">10.1113/JP275906</ArticleId><ArticleId IdType="pmc">PMC6023833</ArticleId><ArticleId IdType="pubmed">29736957</ArticleId></ArticleIdList></Reference><Reference><Citation>Eguchi H., Tsujino A., Kaibara M., Hayashi H., Shirabe S., Taniyama K., Eguchi K. Acetazolamide acts directly on the human skeletal muscle chloride channel. Muscle Nerve. 2006;34:292&#x2013;297. doi: 10.1002/mus.20585.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/mus.20585</ArticleId><ArticleId IdType="pubmed">16770776</ArticleId></ArticleIdList></Reference><Reference><Citation>Altamura C., Lucchiari S., Sahbani D., Ulzi G., Comi G.P., D&#x2019;Ambrosio P., Petillo R., Politano L., Vercelli L., Mongini T., et al. The analysis of myotonia congenita mutations discloses functional clusters of amino acids within CBS2 domain and C-terminal peptide of ClC-1 channel. Hum. Mutat. 2018;39:1273&#x2013;1283. doi: 10.1002/humu.23581.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/humu.23581</ArticleId><ArticleId IdType="pubmed">29935101</ArticleId></ArticleIdList></Reference><Reference><Citation>Altamura C., Fonzino A., Tarantino N., Conte E., Liantonio A., Imbrici P., Carrat&#xf9; M.R., Pierno S., Desaphy J.-F. Increased sarcolemma chloride conductance as one of the mechanisms of action of carbonic anhydrase inhibitors in muscle excitability disorders. Exp. Neurol. 2021;342:113758. doi: 10.1016/j.expneurol.2021.113758.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.expneurol.2021.113758</ArticleId><ArticleId IdType="pubmed">33991525</ArticleId></ArticleIdList></Reference><Reference><Citation>Cozzoli A., Liantonio A., Conte E., Cannone M., Massari A.M., Giustino A., Scaramuzzi A., Pierno S., Mantuano P., Capogrosso R.F., et al. Angiotensin II modulates mouse skeletal muscle resting conductance to chloride and potassium ions and calcium homeostasis via the AT1 receptor and NADPH oxidase. Am. J. Physiol. Cell Physiol. 2014;307:C634&#x2013;C647. doi: 10.1152/ajpcell.00372.2013.</Citation><ArticleIdList><ArticleId IdType="doi">10.1152/ajpcell.00372.2013</ArticleId><ArticleId IdType="pmc">PMC4187056</ArticleId><ArticleId IdType="pubmed">25080489</ArticleId></ArticleIdList></Reference><Reference><Citation>Camerino G.M., Bouch&#xe8; M., De Bellis M., Cannone M., Liantonio A., Musaraj K., Romano R., Smeriglio P., Madaro L., Giustino A., et al. Protein kinase C theta (PKC&#x3b8;) modulates the ClC-1 chloride channel activity and skeletal muscle phenotype: A biophysical and gene expression study in mouse models lacking the PKC&#x3b8;. Pflugers Arch. 2014;466:2215&#x2013;2228. doi: 10.1007/s00424-014-1495-1.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s00424-014-1495-1</ArticleId><ArticleId IdType="pubmed">24643479</ArticleId></ArticleIdList></Reference><Reference><Citation>Gillon A., Nielsen K., Steel C., Cornwall J., Sheard P. Exercise attenuates age-associated changes in motoneuron number, nucleocytoplasmic transport proteins and neuromuscular health. GeroScience. 2018;40:177&#x2013;192. doi: 10.1007/s11357-018-0020-4.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s11357-018-0020-4</ArticleId><ArticleId IdType="pmc">PMC5964256</ArticleId><ArticleId IdType="pubmed">29736782</ArticleId></ArticleIdList></Reference><Reference><Citation>Sailani M.R., Halling J.F., M&#xf8;ller H.D., Lee H., Plomgaard P., Pilegaard H., Snyder M.P., Regenberg B. Lifelong physical activity is associated with promoter hypomethylation of genes involved in metabolism, myogenesis, contractile properties and oxidative stress resistance in aged human skeletal muscle. Sci. Rep. 2019;9:3272. doi: 10.1038/s41598-018-37895-8.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41598-018-37895-8</ArticleId><ArticleId IdType="pmc">PMC6397284</ArticleId><ArticleId IdType="pubmed">30824849</ArticleId></ArticleIdList></Reference><Reference><Citation>Ruegsegger G.N., Booth F.W. Health benefits of exercise. Cold Spring Harb. Perspect. Med. 2018;8:a029694. doi: 10.1101/cshperspect.a029694.</Citation><ArticleIdList><ArticleId IdType="doi">10.1101/cshperspect.a029694</ArticleId><ArticleId IdType="pmc">PMC6027933</ArticleId><ArticleId IdType="pubmed">28507196</ArticleId></ArticleIdList></Reference><Reference><Citation>Cieminski K., Flis D.J., Dzik K., Kaczor J.J., Czyrko E., Halon-Golabek M., Wieckowski M.R., Antosiewicz J., Ziolkowski W. Swim training affects Akt signaling and ameliorates loss of skeletal muscle mass in a mouse model of amyotrophic lateral sclerosis. Sci. Rep. 2021;11:20899. doi: 10.1038/s41598-021-00319-1.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41598-021-00319-1</ArticleId><ArticleId IdType="pmc">PMC8536703</ArticleId><ArticleId IdType="pubmed">34686697</ArticleId></ArticleIdList></Reference><Reference><Citation>Bostr&#xf6;m P., Wu J., Jedrychowski M.P., Korde A., Ye L., Lo J.C., Rasbach K.A., Bostr&#xf6;m E.A., Choi J.H., Long J.Z., et al. A PGC1-&#x3b1;-dependent myokine that drives brown-fat-like development of white fat and thermogenesis. Nature. 2012;481:463&#x2013;468. doi: 10.1038/nature10777.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/nature10777</ArticleId><ArticleId IdType="pmc">PMC3522098</ArticleId><ArticleId IdType="pubmed">22237023</ArticleId></ArticleIdList></Reference><Reference><Citation>Askari H., Rajani S.F., Poorebrahim M., Haghi-Aminjan H., Raeis-Abdollahi E., Abdollahi M. A glance at the therapeutic potential of irisin against diseases involving inflammation, oxidative stress, and apoptosis: An introductory review. Pharmacol. Res. 2018;129:44&#x2013;55. doi: 10.1016/j.phrs.2018.01.012.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.phrs.2018.01.012</ArticleId><ArticleId IdType="pubmed">29414191</ArticleId></ArticleIdList></Reference><Reference><Citation>Sumsuzzman D.M., Jin Y., Choi J., Yu J.H., Lee T.H., Hong Y. Pathophysiological role of endogenous irisin against tumorigenesis and metastasis: Is it a potential biomarker and therapeutic? Tumour. Biol. 2019;41:1010428319892790. doi: 10.1177/1010428319892790.</Citation><ArticleIdList><ArticleId IdType="doi">10.1177/1010428319892790</ArticleId><ArticleId IdType="pubmed">31815594</ArticleId></ArticleIdList></Reference><Reference><Citation>Lunetta C., Lizio A., Tremolizzo L., Ruscica M., Macchi C., Riva N., Weydt P., Corradi E., Magni P., Sansone V. Serum irisin is upregulated in patients affected by amyotrophic lateral sclerosis and correlates with functional and metabolic status. J. Neurol. 2018;265:3001&#x2013;3008. doi: 10.1007/s00415-018-9093-3.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s00415-018-9093-3</ArticleId><ArticleId IdType="pubmed">30350169</ArticleId></ArticleIdList></Reference><Reference><Citation>Cannon S.C. Channelopathies of skeletal muscle excitability. Compr. Physiol. 2015;5:761&#x2013;790.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4754081</ArticleId><ArticleId IdType="pubmed">25880512</ArticleId></ArticleIdList></Reference><Reference><Citation>Imbrici P., Maggi L., Mangiatordi G.F., Dinardo M.M., Altamura C., Brugnoni R., Alberga D., Pinter G.L., Ricci G., Siciliano G., et al. ClC-1 mutations in myotonia congenita patients: Insights into molecular gating mechanisms and genotype-phenotype correlation. J. Physiol. 2015;593:4181&#x2013;4199. doi: 10.1113/JP270358.</Citation><ArticleIdList><ArticleId IdType="doi">10.1113/JP270358</ArticleId><ArticleId IdType="pmc">PMC4594292</ArticleId><ArticleId IdType="pubmed">26096614</ArticleId></ArticleIdList></Reference><Reference><Citation>Imbrici P., Altamura C., Camerino G.M., Mangiatordi G.F., Conte E., Maggi L., Brugnoni R., Musaraj K., Caloiero R., Alberga D., et al. Multidisciplinary study of a new ClC-1 mutation causing myotonia congenita: A paradigm to understand and treat ion channelopathies. FASEB J. 2016;30:3285&#x2013;3295. doi: 10.1096/fj.201500079R.</Citation><ArticleIdList><ArticleId IdType="doi">10.1096/fj.201500079R</ArticleId><ArticleId IdType="pmc">PMC5024700</ArticleId><ArticleId IdType="pubmed">27324117</ArticleId></ArticleIdList></Reference><Reference><Citation>Altamura C., Desaphy J.-F., Conte D., De Luca A., Imbrici P. Skeletal muscle ClC-1 chloride channels in health and diseases. Pflugers Arch. 2020;472:961&#x2013;975. doi: 10.1007/s00424-020-02376-3.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s00424-020-02376-3</ArticleId><ArticleId IdType="pubmed">32361781</ArticleId></ArticleIdList></Reference><Reference><Citation>Desaphy J.-F., Altamura C., Vicart S., Fontaine B. Targeted Therapies for Skeletal Muscle Ion Channelopathies: Systematic Review and Steps Towards Precision Medicine. J. Neuromuscul. Dis. 2021;8:357&#x2013;381. doi: 10.3233/JND-200582.</Citation><ArticleIdList><ArticleId IdType="doi">10.3233/JND-200582</ArticleId><ArticleId IdType="pmc">PMC8203248</ArticleId><ArticleId IdType="pubmed">33325393</ArticleId></ArticleIdList></Reference><Reference><Citation>Waters C.W., Varuzhanyan G., Talmadge R.J., Voss A.A. Huntington disease skeletal muscle is hyperexcitable owing to chloride and potassium channel dysfunction. Proc. Natl. Acad. Sci. USA. 2013;110:9160&#x2013;9165. doi: 10.1073/pnas.1220068110.</Citation><ArticleIdList><ArticleId IdType="doi">10.1073/pnas.1220068110</ArticleId><ArticleId IdType="pmc">PMC3670332</ArticleId><ArticleId IdType="pubmed">23671115</ArticleId></ArticleIdList></Reference><Reference><Citation>Camerino G.M., Musumeci O., Conte E., Musaraj K., Fonzino A., Barca E., Marino M., Rodolico C., Tricarico D., Camerino C., et al. Risk of Myopathy in Patients in Therapy with Statins: Identification of Biological Markers in a Pilot Study. Front. Pharmacol. 2017;8:500. doi: 10.3389/fphar.2017.00500.</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fphar.2017.00500</ArticleId><ArticleId IdType="pmc">PMC5529355</ArticleId><ArticleId IdType="pubmed">28798690</ArticleId></ArticleIdList></Reference><Reference><Citation>Mantuano P., Boccanegra B., Bianchini G., Conte E., De Bellis M., Sanarica F., Camerino G.M., Pierno S., Cappellari O., Allegretti M., et al. BCAAs and Di-Alanine supplementation in the prevention of skeletal muscle atrophy: Preclinical evaluation in a murine model of hind limb unloading. Pharmacol. Res. 2021;171:105798. doi: 10.1016/j.phrs.2021.105798.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.phrs.2021.105798</ArticleId><ArticleId IdType="pubmed">34352400</ArticleId></ArticleIdList></Reference><Reference><Citation>Desaphy J.-F., Pierno S., Liantonio A., Giannuzzi V., Digennaro C., Dinardo M.M., Camerino G.M., Ricciuti P., Brocca L., Pellegrino M.A., et al. Antioxidant treatment of hindlimb-unloaded mouse counteracts fiber type transition but not atrophy of disused muscles. Pharmacol. Res. 2010;61:553&#x2013;563. doi: 10.1016/j.phrs.2010.01.012.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.phrs.2010.01.012</ArticleId><ArticleId IdType="pubmed">20116431</ArticleId></ArticleIdList></Reference><Reference><Citation>Pierno S., De Luca A., Desaphy J.-F., Fraysse B., Liantonio A., Didonna M.P., Lograno M., Cocchi D., Smith R.G., Camerino D.C. Growth hormone secretagogues modulate the electrical and contractile properties of rat skeletal muscle through a ghrelin-specific receptor. Br. J. Pharmacol. 2003;139:575&#x2013;584. doi: 10.1038/sj.bjp.0705284.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/sj.bjp.0705284</ArticleId><ArticleId IdType="pmc">PMC1573883</ArticleId><ArticleId IdType="pubmed">12788817</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle></PubmedArticleSet>